최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Biomolecules & therapeutics, v.30 no.5, 2022년, pp.418 - 426
Cho, Jaewon (Department of Pharmacy, Kangwon National University) , Tae, Nara (Kangwon Institute of Inclusive Technology, Kangwon National University) , Ahn, Jae-Hee (Department of Pharmacy, Kangwon National University) , Chang, Sun-Young (College of Pharmacy, Ajou University) , Ko, Hyun-Jeong (Department of Pharmacy, Kangwon National University) , Kim, Dae Hee (Department of Pharmacy, Kangwon National University)
Chimeric antigen receptor T (CAR-T) cell therapy is one of the promising anticancer treatments. It shows a high overall response rate with complete response to blood cancer. However, there is a limitation to solid tumor treatment. Additionally, this currently approved therapy exhibits side effects s...
Ahn J. H. Lee B. H. Kim S. E. Kwon B. E. Jeong H. Choi J. R. Kim M. J. Park Y. Kim B. S. Kim D. H. Ko H. J. 2021 A novel anti-PD-L1 antibody exhibits antitumor effects on multiple myeloma in murine models via antibody-dependent cellular cytotoxicity Biomol. Ther. (Seoul) 29 166 174 10.4062/biomolther.2020.131 33139584
Alegre M. L. Tso J. Y. Sattar H. A. Smith J. Desalle F. Cole M. Bluestone J. A. 1995 An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity J. Immunol. 155 1544 1555 7636216
Baird J. H. Frank M. J. Craig J. Patel S. Spiegel J. Y. Sahaf B. Oak J. S. Younes S. F. Ozawa M. G. Yang E. Natkunam Y. Tamaresis J. Ehlinger Z. Reynolds W. D. Arai S. Johnston L. Lowsky R. Meyer E. Negrin R. S. Rezvani A. R. Shiraz P. Sidana S. Weng W. K. Davis K. L. Ramakrishna S. Schultz L. Mullins C. Jacob A. Kirsch I. Feldman S. A. Mackall C. L. Miklos D. B. Muffly L. 2021 CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma Blood 137 2321 2325 10.1182/blood.2020009432 33512414
Choi J. R. Kim M. J. Tae N. Wi T. M. Kim S. H. Lee E. S. Kim D. H. 2020 BLI-based functional assay in phage display benefits the development of a PD-L1-targeting therapeutic antibody Viruses 12 684 10.3390/v12060684 89ef47725f7e408ab4e0d9b3bbb6a168 32630442
Chung Y. Kim B. S. Kim Y. J. Ko H. J. Ko S. Y. Kim D. H. Kang C. Y. 2006 CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo Cancer Res. 66 6843 6850 10.1158/0008-5472.CAN-06-0889 16818662
Edeline J. Houot R. Marabelle A. Alcantara M. 2021 CAR-T cells and BiTEs in solid tumors: challenges and perspectives J. Hematol. Oncol. 14 65 10.1186/s13045-021-01067-5 2bbb8d605fec4173a17b12b48f0231fe 33874996
Franquiz M. J. Short N. J. 2020 Blinatumomab for the treatment of adult B-cell acute lymphoblastic leukemia: toward a new era of targeted immunotherapy Biol. Targets Ther. 14 23 34 10.2147/BTT.S202746 32103893
Geuijen C. Tacken P. Wang L. C. Klooster R. van Loo P. F. Zhou J. Mondal A. Liu Y. B. Kramer A. Condamine T. Volgina A. Hendriks L. J. A. van der Maaden H. Rovers E. Engels S. Fransen F. den Blanken-Smit R. Zondag-van der Zande V. Basmeleh A. Bartelink W. Kulkarni A. Marissen W. Huang C. Y. Hall L. Harvey S. Kim S. Martinez M. O'Brien S. Moon E. Albelda S. Kanellopoulou C. Stewart S. Nastri H. Bakker A. B. H. Scherle P. Logtenberg T. Hollis G. de Kruif J. Huber R. Mayes P. A. Throsby M. 2021 A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade Nat. Commun. 12 4445 10.1038/s41467-021-24767-5 4044cbbb9c1d4937ac08f857eba69b30 34290245
Horn L. A. Ciavattone N. G. Atkinson R. Woldergerima N. Wolf J. Clements V. K. Sinha P. Poudel M. Ostrand-Rosenberg S. 2017 CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice Oncotarget 8 57964 57980 10.18632/oncotarget.19865 28938530
Jeong S. Park E. Kim H. D. Sung E. Kim H. Jeon J. Kim Y. Jung U. J. Son Y. G. Hong Y. Lee H. Lee S. Lim Y. Won J. Jeon M. Hwang S. Fang L. Jiang W. Wang Z. Shin E. C. Park S. H. Jung J. 2021 Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade J. Immunother. Cancer 9 e002428 10.1136/jitc-2021-002428 f928715e9bd14a19be6842809c144bf9 34230109
Jiang H. Ni H. Zhang P. Guo X. Wu M. Shen H. Wang J. Wu W. Wu Z. Ding J. Tang R. Zhou S. Chen B. Yu M. Jing H. Liu J. 2021 PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity Oncoimmunology 10 1943180 10.1080/2162402X.2021.1943180 34239776
Kershaw M. H. Westwood J. A. Darcy P. K. 2013 Gene-engineered T cells for cancer therapy Nat. Rev. Cancer 13 525 541 10.1038/nrc3565 23880905
Kershaw M. H. Westwood J. A. Parker L. L. Wang G. Eshhar Z. Mavroukakis S. A. White D. E. Wunderlich J. R. Canevari S. Rogers-Freezer L. Chen C. C. Yang J. C. Rosenberg S. A. Hwu P. 2006 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin. Cancer Res. 12 6106 6115 10.1158/1078-0432.CCR-06-1183 17062687
Ko H. J. Kim Y. J. Kim Y. S. Chang W. S. Ko S. Y. Chang S. Y. Sakaguchi S. Kang C. Y. 2007 A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model Cancer Res. 67 7477 7486 10.1158/0008-5472.CAN-06-4639 17671218
Li Y. Kurlander R. J. 2010 Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation J. Transl. Med. 8 104 10.1186/1479-5876-8-104 20977748
Liu Q. Sun Z. Chen L. 2020 Memory T cells: strategies for optimizing tumor immunotherapy Protein Cell 11 549 564 10.1007/s13238-020-00707-9 f7f324e589c04dc2a6ecb736bbbecb13 32221812
Maude S. L. Laetsch T. W. Buechner J. Rives S. Boyer M. Bittencourt H. Bader P. Verneris M. R. Stefanski H. E. Myers G. D. Qayed M. De Moerloose B. Hiramatsu H. Schlis K. Davis K. L. Martin P. L. Nemecek E. R. Yanik G. A. Peters C. Baruchel A. Boissel N. Mechinaud F. Balduzzi A. Krueger J. June C. H. Levine B. L. Wood P. Taran T. Leung M. Mueller K. T. Zhang Y. Sen K. Lebwohl D. Pulsipher M. A. Grupp S. A. 2018 Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N. Engl. J. Med. 378 439 448 10.1056/NEJMoa1709866 29385370
Moon E. K. Carpenito C. Sun J. Wang L. C. Kapoor V. Predina J. Powell D. J. Jr. Riley J. L. June C. H. Albelda S. M. 2011 Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor Clin. Cancer Res. 17 4719 4730 10.1158/1078-0432.CCR-11-0351 21610146
Moon E. K. Wang L. C. Dolfi D. V. Wilson C. B. Ranganathan R. Sun J. Kapoor V. Scholler J. Puré E. Milone M. C. June C. H. Riley J. L. Wherry E. J. Albelda S. M. 2014 Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors Clin. Cancer Res. 20 4262 4273 10.1158/1078-0432.CCR-13-2627 24919573
Neelapu S. S. Locke F. L. Bartlett N. L. Lekakis L. J. Miklos D. B. Jacobson C. A. Braunschweig I. Oluwole O. O. Siddiqi T. Lin Y. Timmerman J. M. Stiff P. J. Friedberg J. W. Flinn I. W. Goy A. Hill B. T. Smith M. R. Deol A. Farooq U. McSweeney P. Munoz J. Avivi I. Castro J. E. Westin J. R. Chavez J. C. Ghobadi A. Komanduri K. V. Levy R. Jacobsen E. D. Witzig T. E. Reagan P. Bot A. Rossi J. Navale L. Jiang Y. Aycock J. Elias M. Chang D. Wiezorek J. Go W. Y. 2017 Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N. Engl. J. Med. 377 2531 2544 10.1056/NEJMoa1707447 29226797
Newick K. O'Brien S. Moon E. Albelda S. M. 2017 CAR T cell therapy for solid tumors Annu. Rev. Med. 68 139 152 10.1146/annurev-med-062315-120245 27860544
Principe N. Kidman J. Goh S. Tilsed C. M. Fisher S. A. Fear V. S. Forbes C. A. Zemek R. M. Chopra A. Watson M. Dick I. M. Boon L. Holt R. A. Lake R. A. Nowak A. K. Lesterhuis W. J. McDonnell A. M. Chee J. 2020 Tumor infiltrating effector memory antigen-specific CD8(+) T cells predict response to immune checkpoint therapy Front. Immunol. 11 584423 10.3389/fimmu.2020.584423 14028b32db2541389131a67ac973ccfb 33262762
Qin S. Xu L. Yi M. Yu S. Wu K. Luo S. 2019 Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 Mol. Cancer 18 155 10.1186/s12943-019-1091-2 7f6ea285e3834011a1ff496a2f1048a8 31690319
Teoh P. J. Chng W. J. 2021 CAR T-cell therapy in multiple myeloma: more room for improvement Blood Cancer J. 11 84 10.1038/s41408-021-00469-5 bb326b5565e34c6d95d81ac310641d49 33927192
Till B. G. Jensen M. C. Wang J. Qian X. Gopal A. K. Maloney D. G. Lindgren C. G. Lin Y. Pagel J. M. Budde L. E. Raubitschek A. Forman S. J. Greenberg P. D. Riddell S. R. Press O. W. 2012 CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results Blood 119 3940 3950 10.1182/blood-2011-10-387969 22308288
Turtle C. J. Hay K. A. Hanafi L. A. Li D. Cherian S. Chen X. Wood B. Lozanski A. Byrd J. C. Heimfeld S. Riddell S. R. Maloney D. G. 2017 Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib J. Clin. Oncol. 35 3010 3020 10.1200/JCO.2017.72.8519 28715249
Waldman A. D. Fritz J. M. Lenardo M. J. 2020 A guide to cancer immunotherapy: from T cell basic science to clinical practice Nat. Rev. Immunol. 20 651 668 10.1038/s41577-020-0306-5 32433532
You G. Won J. Lee Y. Moon D. Park Y. Lee S. H. Lee S. W. 2021 Bispecific antibodies: a smart arsenal for cancer immunotherapies Vaccines 9 724 10.3390/vaccines9070724 f948b667f9af4ceeb9bfca14fd8e65b8 34358141
Yu W. L. Hua Z. C. 2019 Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and safety-a systematic review with meta-analysis Cancers (Basel) 11 47 10.3390/cancers11010047 30621018
Zhang C. Liu J. Zhong J. F. Zhang X. 2017 Engineering CAR-T cells Biomarker Res. 5 22 10.1186/s40364-017-0102-y 28652918
Zheng P. P. Kros J. M. Li J. 2018 Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts Drug Discov. Today 23 1175 1182 10.1016/j.drudis.2018.02.012 29501911
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.